IMGN 289

Drug Profile

IMGN 289

Alternative Names: IMGN-289; R= J-2898-A

Latest Information Update: 12 Jun 2015

Price : $50

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 24 Apr 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 01 Apr 2015 ImmunoGen terminates a phase I trial in Solid tumours (Late-stage disease; Second-line therapy or greater) in USA (IV) (NCT01963715)
  • 09 Oct 2013 Phase-I clinical trials in Solid tumours (late-stage disease, second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top